Capricor Therapeutics Inc (NASDAQ: CAPR)’s stock price has plunge by 9.21relation to previous closing price of 10.21. Nevertheless, the company has seen a 6.39% surge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-03 that NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CAPR.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
Company’s 36-month beta value is 0.85.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CAPR is 40.15M, and currently, short sellers hold a 34.33% ratio of that floaft. The average trading volume of CAPR on June 04, 2025 was 2.07M shares.
CAPR’s Market Performance
CAPR stock saw a decrease of 6.39% in the past week, with a monthly decline of -5.99% and a quarterly a decrease of -18.61%. The volatility ratio for the week is 6.21%, and the volatility levels for the last 30 days are 10.88% for Capricor Therapeutics Inc (CAPR). The simple moving average for the past 20 days is 20.76% for CAPR’s stock, with a -13.48% simple moving average for the past 200 days.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Roth Capital repeating the rating for CAPR by listing it as a “Buy.” The predicted price for CAPR in the upcoming period, according to Roth Capital is $31 based on the research report published on May 20, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $35. The rating they have provided for CAPR stocks is “Overweight” according to the report published on October 21st, 2024.
Oppenheimer gave a rating of “Outperform” to CAPR, setting the target price at $14 in the report published on May 17th of the previous year.
CAPR Trading at 7.47% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.35% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -3.3 for the present operating margin
- 1.0 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -3.17. The total capital return value is set at -0.44. Equity return is now at value -75.39, with -54.19 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.14.
Currently, EBITDA for the company is -41.14 million with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of 27.76. The receivables turnover for the company is 290.2for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.55.
Conclusion
In a nutshell, Capricor Therapeutics Inc (CAPR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
